Literature DB >> 18250556

Effect of nasal continuous positive airway pressure treatment on plasma adrenomedullin levels in patients with obstructive sleep apnea syndrome: roles of nocturnal hypoxia and oxidant stress.

Hiroshi Yamamoto1, Shinji Teramoto, Yasuhiro Yamaguchi, Yasuyoshi Ouchi.   

Abstract

Obstructive sleep apnea syndrome (OSAS) is recognized as one of the risk factors of hypertension and cardiovascular disorders. In the current study, we hypothesized that the hypoxic stress and oxidative stress caused by obstructive sleep apnea would increase circulating adrenomedullin (ADM) levels in untreated OSAS patients as compared to an age and body mass index (BMI)-matched control group and an age-matched, but normal-BMI control group. We further hypothesized that nasal continuous positive airway pressure (nCPAP) treatment may decrease OSAS-induced hypoxic stress, oxidative stress and ADM levels. To examine these hypotheses, we measured circulating ADM and reactive oxygen species (ROS) from leukocytes before and after nCPAP therapy in OSAS patients. The circulating levels of ADM and amount of ROS in untreated OSAS patients were significantly greater than those in the controls. No differences in ADM levels were found between the increased-BMI controls and normal-BMI controls. We observed that nCPAP treatment decreased sleep apneas, nocturnal oxyhemoglobin desaturation, the circulating ADM, and ROS production by leukocytes in OSAS patients. The ADM levels were associated with the magnitude of oxyhemoglobin desaturation rather than the number of sleep apneas. These observations suggest that nCPAP therapy could reduce OSAS-induced nocturnal hypoxemia, generation of ROS, and ADM in patients with OSAS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18250556     DOI: 10.1291/hypres.30.1065

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  5 in total

Review 1.  Inflammation accelerates atherosclerotic processes in obstructive sleep apnea syndrome (OSAS).

Authors:  Alessandra Quercioli; François Mach; Fabrizio Montecucco
Journal:  Sleep Breath       Date:  2010-03-03       Impact factor: 2.816

Review 2.  Treatment alternatives for sleep-disordered breathing in the pediatric population.

Authors:  Ann C Halbower; Brian M McGinley; Philip L Smith
Journal:  Curr Opin Pulm Med       Date:  2008-11       Impact factor: 3.155

3.  Copeptin, pro-atrial natriuretic peptide and pro-adrenomedullin as markers of hypoxic stress in patients with obstructive sleep apnea-a prospective intervention study.

Authors:  Meropi Karakioulaki; Peter Grendelmeier; Werner Strobel; Thomas Schmid; Kathleen Jahn; Leticia Grize; Michael Tamm; Daiana Stolz
Journal:  Respir Res       Date:  2021-04-20

4.  Increased risk of benign prostate hyperplasia in sleep apnea patients: a nationwide population-based study.

Authors:  Ping-Song Chou; Wei-Chiao Chang; Wei-Po Chou; Mu-En Liu; Chiou-Lian Lai; Ching-Kuan Liu; Yan-Chiou Ku; Shih-Jen Tsai; Yii-Her Chou; Wei-Pin Chang
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

5.  Explorating the Involvement of Plasma Sestrin2 in Obstructive Sleep Apnea.

Authors:  Rong Jiang; Qiru Wang; Huifen Zhai; Xiaohua Du; Shibo Sun; Haoyan Wang
Journal:  Can Respir J       Date:  2019-11-03       Impact factor: 2.409

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.